Analyst Tara Bancroft of TD Cowen maintained a Buy rating on Vaxcyte, retaining the price target of $50.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Tara Bancroft’s rating is based on promising data from Vaxcyte’s vaccine trials, which suggest strong potential for their products. The recent Phase II data for VAX-24 in infants showed that non-inferiority criteria for immunogenicity were met for most serotypes, indicating robust immune responses. The dose-dependent increase in immunogenicity without evidence of increased carrier suppression further supports the efficacy of the vaccine, particularly with the optimized dosing strategy being tested in the VAX-31 infant study.
Additionally, the potential for improved titers when VAX-24 is co-administered with a flu vaccine provides an added advantage over existing vaccines like Prevnar. The expectation of positive Phase III data in 2026 and the current undervaluation of Vaxcyte’s stock contribute to the Buy rating. These factors combined suggest a strong outlook for Vaxcyte, making it an attractive investment opportunity.